More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective...

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective inhibitor shows promising clinical activity in Phase ll trial in patients with NRAS mutated melanoma. Shares +2.5% AH.